Karthick Vasudevan, Ramanathan Karuppasamy
Bioinformatics Division, School of Bio Sciences and Technology, Vellore Institute of Technology, Vellore, Tamil Nadu 632014 India.
Springerplus. 2013 Mar 18;2(1):115. doi: 10.1186/2193-1801-2-115. Print 2013 Dec.
The neuraminidase (NA) of the influenza virus is the target of antiviral drug, oseltamivir. Recently, cases are reported that Influenza virus becoming resistant to oseltamivir, necessitating the development of new long-acting antiviral compounds. Most importantly, H274Y mutation in neuraminidase exhibits high levels of resistance to oseltamivir. In this report, a novel class of lead molecule with potential NA inhibitory activity was found from the traditional Chinese medicine database (TCMD) using virtual screening approach. Initially ADME properties of the lead compounds were analyzed with respect to the Lipinski rule of five. Subsequently, the data reduction was carried out by employing molecular docking study. Final validation was done by means of molecular dynamic simulations. The toxicity profiles for the screened compound were also analyzed. The result indicates that neoglucobrassicin (a compound derived from TCMD) become a promising lead compound and be effective in treating oseltamivir-resistant influenza virus strains.
流感病毒的神经氨酸酶(NA)是抗病毒药物奥司他韦的作用靶点。最近,有报道称流感病毒对奥司他韦产生了耐药性,因此需要开发新的长效抗病毒化合物。最重要的是,神经氨酸酶中的H274Y突变对奥司他韦表现出高度耐药性。在本报告中,使用虚拟筛选方法从中药数据库(TCMD)中发现了一类具有潜在NA抑制活性的新型先导分子。首先,根据Lipinski五规则分析了先导化合物的ADME性质。随后,通过分子对接研究进行数据简化。最终通过分子动力学模拟进行验证。还分析了筛选化合物的毒性概况。结果表明,新葡萄糖芥苷(一种源自TCMD的化合物)成为一种有前景的先导化合物,对治疗耐奥司他韦的流感病毒株有效。